Clarus Therapeutics Holdings, Inc.

Blue Water Acquisition Corporation (Nasdaq: BLUW) was a healthcare- and medtech-focused special purpose acquisition company that completed its initial public offering in 2021. In May 2021, the company announced a definitive business combination with Clarus Therapeutics Holdings, Inc., a commercial-stage specialty pharmaceutical firm recognized for JATENZO, the first FDA-approved oral softgel testosterone replacement therapy. The transaction subsequently closed, transitioning Clarus Therapeutics into a publicly traded company via the de-SPAC process. The deal is recorded as closed in SPAC market data, representing a completed transaction within the broader healthcare and pharmaceutical segment. Sign up at SpacDesk for full filing details, deal timelines, and analytics on BLUW and the entire SPAC universe.

SPAC Counterparty (1)